NEW YORK (GenomeWeb News) - Sloning Biotechnology and BioMérieux will collaborate on a feasibility study to develop gene variants for an enzyme BioMérieux can use in its in vitro diagnostics development programs, Sloning said today.
Sloning, based in Munich, Germany, said it will use its Slonomics gene-synthesis technology to offer BioMérieux “a gene library with a full set of ratio-controlled mutants.”
BioMérieux plans to use the results of the study to identify an enzyme with “with significantly enhanced characteristics” for molecular diagnostics applications.
Financial terms of the agreement were not released.